CV Sciences, Inc.: peers
CV Sciences, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
CV Sciences, Inc., Healthy Extracts Inc., Neurogene Inc., Resonate Blends, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | CV Sciences, Inc.base CVSI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Healthy Extracts Inc. HYEX · 🇺🇸 US Percentile in Healthcare Percentile in USA | TherapeuticsMD, Inc. TXMD · 🇺🇸 US Percentile in Healthcare Percentile in USA | Cosmos Holdings COSM · 🇺🇸 US Percentile in Healthcare Percentile in USA | Neurogene Inc. NGNE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Rockwell Medical, Inc. RMTI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Resonate Blends, Inc. KOAN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Scynexis, Inc. SCYX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $20 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one6th of 8 | $19 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one7th of 8 | $23 MOct 14, 2026 · Market data5th of 8 | $28 MOct 30, 2026 · Market data4th of 8 | $30 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8 | $32 MOct 16, 2026 · Market data2nd of 8 | $12 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one8th of 8 | $38 MOct 30, 2026 · Market data1st of 8 | $25 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $14 MFY2025 · SEC4th of 7 | $5 MFY2025 · SEC5th of 7 | $3 MFY2025 · SEC6th of 7 | $65 MFY2025 · SEC2nd of 7 | —— | $69 MFY2025 · SEC1st of 7 | $2 MFY2024 · SEC7th of 7 | $21 MFY2025 · SEC3rd of 7 | $14 M7 ranked |
| Net income (Higher is better) | $-1 MFY2025 · SEC3rd of 8 | $-1 MFY2025 · SEC2nd of 8 | $-1 MFY2025 · SEC1st of 8 | $-19 MFY2025 · SEC7th of 8 | $-90 MFY2025 · SEC8th of 8 | $-5 MFY2025 · SEC5th of 8 | $-2 MFY2024 · SEC4th of 8 | $-9 MFY2025 · SEC6th of 8 | $-4 M8 ranked |
| Employees (Better neither way: ranked highest first) | 44December 31, 2025 · Profile3rd of 4 | —— | —— | 163December 31, 2025 · Profile1st of 4 | 131March 16, 2026 · Profile2nd of 4 | —— | —— | 18March 1, 2026 · Profile4th of 4 | 884 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | —— | —— | -23.3%30 days to Oct 30, 2026 · Market dataonly one with it | -23.3%— |
| Revenue growth (Higher is better) | -12.2%FY2025 · SEC5th of 614th10th | +45.0%FY2025 · SEC3rd of 683rd91st | +71.6%FY2025 · SEC2nd of 689th94th | +19.9%FY2025 · SEC4th of 668th79th | ———— | -31.8%FY2025 · SEC6th of 68th4th | ———— | +449.3%FY2025 · SEC1st of 699th99th | +32.5%6 ranked |
| Revenue growth, 3 years a year (Higher is better) | -5.2%FY2025 · SEC4th of 416th18th | +26.1%FY2025 · SEC1st of 479th90th | ———— | +9.0%FY2025 · SEC2nd of 451st66th | ———— | -1.6%FY2025 · SEC3rd of 423rd27th | ———— | ———— | +3.7%4 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 49.0%FY2025 · SEC3rd of 535th62nd | 53.7%FY2025 · SEC2nd of 542nd67th | ———— | 12.1%FY2025 · SEC5th of 55th10th | ———— | 16.9%FY2025 · SEC4th of 57th16th | 65.3%FY2024 · SEC1st of 560th78th | ———— | 49.0%5 ranked |
| Operating margin (Higher is better) | -3.4%FY2025 · SEC1st of 653rd34th | ———— | -145.4%FY2025 · SEC6th of 619th8th | -25.6%FY2025 · SEC3rd of 639th20th | ———— | -6.8%FY2025 · SEC2nd of 651st30th | -89.5%FY2024 · SEC5th of 625th11th | -78.0%FY2025 · SEC4th of 626th12th | -51.8%6 ranked |
| Net margin (Higher is better) | -7.0%FY2025 · SEC1st of 751st30th | -19.5%FY2025 · SEC4th of 743rd22nd | -18.9%FY2025 · SEC3rd of 743rd22nd | -29.3%FY2025 · SEC5th of 739th18th | ———— | -7.7%FY2025 · SEC2nd of 750th29th | -112.1%FY2024 · SEC7th of 721st9th | -41.8%FY2025 · SEC6th of 733rd16th | -19.5%7 ranked |
| Free cash flow margin (Higher is better) | -3.8%FY2025 · SEC2nd of 446th27th | ———— | ———— | -13.0%FY2025 · SEC3rd of 441st20th | ———— | -1.7%FY2025 · SEC1st of 449th30th | -54.2%FY2024 · SEC4th of 427th12th | ———— | -8.4%4 ranked |
| Return on equity (Higher is better) | -58.7%FY2025 · SEC6th of 739th16th | -7.3%FY2025 · SEC2nd of 768th35th | -2.1%FY2025 · SEC1st of 771st40th | -89.1%FY2025 · SEC7th of 728th12th | -31.4%FY2025 · SEC5th of 753rd23rd | -15.3%FY2025 · SEC3rd of 763rd30th | ———— | -16.5%FY2025 · SEC4th of 762nd29th | -16.5%7 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | 6.9×price Oct 14, 2026 · Market data1st of 464th84th | 0.4×price Oct 30, 2026 · Market data4th of 46th11th | ———— | 0.4×price Oct 16, 2026 · Market data3rd of 47th14th | ———— | 1.9×price Oct 30, 2026 · Market data2nd of 431st46th | 1.2×4 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | 0.8×price Oct 14, 2026 · Market data3rd of 416th16th | 1.5×price Oct 30, 2026 · Market data1st of 431st37th | ———— | 0.9×price Oct 16, 2026 · Market data2nd of 416th16th | ———— | 0.8×price Oct 30, 2026 · Market data4th of 415th14th | 0.9×4 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | -30.2%price Oct 30, 2026 · Market data2nd of 326th11th | ———— | -3.7%price Oct 16, 2026 · Market data1st of 357th29th | ———— | -142.0%price Oct 30, 2026 · Market data3rd of 34th1st | -30.2%3 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 1.1×FY2025 · SEC3rd of 377th71st | ———— | ———— | 0.2×FY2025 · SEC1st of 333rd24th | ———— | 0.2×FY2025 · SEC2nd of 335th26th | ———— | ———— | 0.2×3 ranked |
| Interest cover (Higher is better) | ———— | ———— | -439.0×FY2025 · SEC2nd of 27th2nd | -8.8×FY2025 · SEC1st of 244th24th | ———— | ———— | ———— | ———— | -223.9×2 ranked |
| Piotroski F-score (Higher is better) | 6 of 9FY2025 · SEC1st of 3 | —— | —— | 5 of 9FY2025 · SEC2nd of 3 | —— | 3 of 9FY2025 · SEC3rd of 3 | —— | —— | 5.0 of 93 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 3 of 15FY2025 · Scorecard7th of 8 | 5 of 10FY2025 · Scorecard1st of 8 | 5 of 17FY2025 · Scorecard5th of 8 | 7 of 22FY2025 · Scorecard3rd of 8 | 1 of 8FY2025 · Scorecard8th of 8 | 7 of 22FY2025 · Scorecard3rd of 8 | 2 of 8FY2024 · Scorecard6th of 8 | 6 of 17FY2025 · Scorecard2nd of 8 | 31% passed8 ranked |
| Valuation checks (Higher is better) | —— | —— | 1 of 4FY2025 · Scorecard4th of 4 | 2 of 5FY2025 · Scorecard1st of 4 | —— | 2 of 5FY2025 · Scorecard1st of 4 | —— | 2 of 5FY2025 · Scorecard1st of 4 | 40% passed4 ranked |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecard6th of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 2 of 3FY2025 · Scorecard2nd of 8 | 4 of 6FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard8th of 8 | 1 of 6FY2025 · Scorecard6th of 8 | 1 of 2FY2024 · Scorecard5th of 8 | 2 of 3FY2025 · Scorecard2nd of 8 | 58% passed8 ranked |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 0 of 3FY2025 · Scorecard5th of 8 | 1 of 5FY2025 · Scorecard2nd of 8 | 1 of 4FY2024 · Scorecard1st of 8 | 1 of 5FY2025 · Scorecard2nd of 8 | 10% passed8 ranked |
| Financial health checks (Higher is better) | 1 of 3FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard7th of 8 | 1 of 4FY2025 · Scorecard5th of 8 | 1 of 5FY2025 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard2nd of 8 | 3 of 5FY2025 · Scorecard1st of 8 | 0 of 2FY2024 · Scorecard7th of 8 | 1 of 3FY2025 · Scorecard3rd of 8 | 29% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard2nd of 6 | —— | 1 of 1FY2025 · Scorecard1st of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | 0 of 1FY2025 · Scorecard2nd of 6 | —— | 0 of 1FY2025 · Scorecard2nd of 6 | 0% passed6 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | 32.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 7.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 115.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 7.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5 | —— | 46.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 32.1%5 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | 462026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5 | 302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5 | 1322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5 | 272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5 | —— | 422026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5 | 425 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | -2.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 3 | +1.0 pp2026-Q2 against 2026-Q1 · 13F1st of 3 | -22.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 3 | —— | —— | —— | -2.3 pp3 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = CV Sciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Healthy Extracts Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; TherapeuticsMD, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Cosmos Holdings: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neurogene Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rockwell Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Resonate Blends, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Scynexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| CV Sciences, Inc. | -3.4%FY2025 | 53rd percentile in Healthcaremedian -7.7%, 674 companies | 34th percentile in USAmedian 3.5%, 2,594 companies |
| Healthy Extracts Inc. | — | — | — |
| TherapeuticsMD, Inc. | -145.4%FY2025 | 19th percentile in Healthcaremedian -7.7%, 674 companies | 8th percentile in USAmedian 3.5%, 2,594 companies |
| Cosmos Holdings | -25.6%FY2025 | 39th percentile in Healthcaremedian -7.7%, 674 companies | 20th percentile in USAmedian 3.5%, 2,594 companies |
| Neurogene Inc. | — | — | — |
| Rockwell Medical, Inc. | -6.8%FY2025 | 51st percentile in Healthcaremedian -7.7%, 674 companies | 30th percentile in USAmedian 3.5%, 2,594 companies |
| Resonate Blends, Inc. | -89.5%FY2024 | 25th percentile in Healthcaremedian -7.7%, 674 companies | 11th percentile in USAmedian 3.5%, 2,594 companies |
| Scynexis, Inc. | -78.0%FY2025 | 26th percentile in Healthcaremedian -7.7%, 674 companies | 12th percentile in USAmedian 3.5%, 2,594 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | CV Sciences, Inc. | Healthy Extracts Inc. | TherapeuticsMD, Inc. | Cosmos Holdings | Neurogene Inc. | Rockwell Medical, Inc. | Resonate Blends, Inc. | Scynexis, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $14 MSEC4th | $5 MSEC5th | $3 MSEC6th | $65 MSEC2nd | — | $69 MSEC1st | — | $21 MSEC3rd |
| 2024 | $16 MSEC3rd | $3 MSEC5th | $2 MSEC7th | $54 MSEC2nd | $1 MSEC8th | $101 MSEC1st | $2 MSEC6th | $4 MSEC4th |
| 2023 | $16 MSEC3rd | $2 MSEC4th | $1 MSEC5th | $53 MSEC2nd | — | $84 MSEC1st | $0 MSEC6th | — |
| 2022 | $16 MSEC4th | $2 MSEC6th | $70 MSEC2nd | $50 MSEC3rd | — | $73 MSEC1st | $0 MSEC7th | $5 MSEC5th |
| 2021 | $20 MSEC3rd | $2 MSEC5th | — | $56 MSEC2nd | — | $62 MSEC1st | $0 MSEC6th | $13 MSEC4th |
| 2020 | $24 MSEC4th | $1 MSEC5th | $65 MSEC1st | $55 MSEC3rd | — | $62 MSEC2nd | — | — |
| 2019 | $54 MSEC2nd | $1 MSEC6th | $50 MSEC3rd | $40 MSEC4th | — | $61 MSEC1st | $1 MSEC5th | $0 MSEC7th |
| 2018 | $48 MSEC2nd | $0 MSEC8th | $16 MSEC5th | $37 MSEC3rd | $25 MSEC4th | $63 MSEC1st | $1 MSEC6th | $0 MSEC7th |
| 2017 | $21 MSEC3rd | $0 MSEC7th | $17 MSEC4th | $30 MSEC2nd | — | $57 MSEC1st | $1 MSEC5th | $0 MSEC6th |
| 2016 | $11 MSEC3rd | $0 MSEC7th | $19 MSEC2nd | $7 MSEC4th | — | $53 MSEC1st | $0 MSEC5th | $0 MSEC6th |
| 2015 | $12 MSEC3rd | $0 MSEC6th | $20 MSEC2nd | — | — | $55 MSEC1st | $0 MSEC4th | $0 MSEC5th |
| 2014 | $10 MSEC4th | — | $15 MSEC2nd | $8 MSEC5th | — | $54 MSEC1st | $0 MSEC6th | $12 MSEC3rd |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of CV Sciences, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Healthy Extracts Inc.HYEX · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $19 M (last known, Jul 30, 2023) · revenue $5 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- TherapeuticsMD, Inc.TXMD · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $23 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $23 M (Oct 14, 2026) · revenue $3 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)In the group
- Cosmos HoldingsCOSM · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $28 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $28 M (Oct 30, 2026) · revenue $65 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Neurogene Inc.NGNE · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $30 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $30 M (last known, Jul 30, 2023) · revenue $0 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Rockwell Medical, Inc.RMTI · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $32 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $32 M (Oct 16, 2026) · revenue $69 M (year to December 2025)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Resonate Blends, Inc.KOAN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $12 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $12 M (last known, Jan 7, 2022) · revenue $2 M (year to December 2024)97 of 100 (industry or sector 50 + size 27 + country 15 + figures on file 5)In the group
- Scynexis, Inc.SCYX · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $38 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $38 M (Oct 30, 2026) · revenue $21 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- Bonk, Inc.BNKK · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $10 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $10 M (Oct 30, 2026) · revenue $2 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)+ Add
- Elite Pharmaceuticals, Inc.ELTP · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $42 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $42 M (last known, Jan 7, 2022) · revenue $149 M (year to March 2026)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Weed Inc.BUDZ · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $9 M market cap against $20 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jul 30, 2023)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Medmen Enterprises Inc.MMEN.CN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $21 M market cap against $20 M · Same country: USAMarket cap $21 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
- Cansortium Inc.TIUM-U.CN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $19 M market cap against $20 M · Same country: USAMarket cap $19 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.